# A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

> **NCT05197049** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 350 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Guselkumab Dose 1
- **DRUG:** Guselkumab Dose 2
- **DRUG:** Guselkumab Dose 3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05197049
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-19
- **Primary completion:** 2023-07-04
- **Final completion:** 2028-10-30
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05197049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05197049, "A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT05197049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*